New study tracks Real-World safety of TEGSEDI for rare nerve disease
Knowledge-focused
Recruiting now
This study follows 240 patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) to monitor the long-term safety of the drug TEGSEDI. Researchers will compare patients who have taken TEGSEDI with those who have not, focusing on side effects like low platel…
Sponsor: Akcea Therapeutics • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:48 UTC